Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives

Therapeutic Innovation and Regulatory Science

Volumn 48, Issue 5, 2014, Pages 601-612

  Sverdlov, Oleksandr ^a   Wong, Weng Kee ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bayesian designs; dose finding; minimum efficacious dose; optimal adaptive designs; seamless phase I II; up and down designs

Indexed keywords

ARTICLE; BAYES THEOREM; COMPARATIVE STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; HUMAN; MODEL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC);

EID: 84910057278     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479014523765     Document Type: Article

References (101)

1. Scannell JW,Blanckley A,Boldon H,Warrington B.Diagnosing the decline in pharmaceutical R&D efficiency.Nat Rev Drug Disc. 2012;11:191-200
2. US Food and Drug Administration. Innovation or stagnation: Challenge and opportunity on the critical path to the new medical products. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf. Accessed February 19, 2014.
3. US Food and Drug Administration. Innovation or stagnation: critical path opportunities list. http://www.fda.gov/downloads/scienceresearch/specialtopics/criticalpathinitiative/criticalpathopportunitiesreports/UCM077258.pdf. Accessed February 19, 2014.
4. Dragalin V.Adaptive designs: terminology and classification.Drug Inf J. 2006;40:425-435
5. Pong A,Chow SCHandbook of Adaptive Designs in Pharmaceutical and Clinical Development. Boca Raton, FL: CRC Press; 2010:
6. Chow SC,Chang MAdaptive Design Methods in Clinical Trials. 2nd ed. Boca Raton, FL: Chapman & Hall / CRC Biostatistics Series; 2011.Boca Raton, FL: Chapman & Hall / CRC Biostatistics Series; 2011:
7. 2006:
8. 2006:
9. 2010:
10. 2010:
11. 2012:
12. Committee for Medicinal Products for Human Use. Reflection paper on methodological issues in confirmatory clinical trials with an adaptive design. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf. Accessed February 19, 2014.
13. US Food and Drug Administration. Guidance for industry: adaptive design clinical trials for drugs and biologics (draft document). http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf. Accessed February 19, 2014.
14. Gallo P,Chuang-Stein C,Dragalin V,Gaydos B,Krams M,Pinheiro J.Adaptive designs in clinical drug development: an executive summary of the PhRMA working group (with discussion).J Biopharm Stat. 2006;16:275-312
15. Chow SC,Chang M.Adaptive design methods in clinical trials: a review.Orphanet J Rare Dis. 2008;3:11
16. Chevret SStatistical Methods for Dose-Finding Experiments. New York, NY: Wiley; 2006:
17. Dragalin VHandbook of Adaptive Designs in Pharmaceutical and Clinical Development. Pong AChow S-C, ed. Boca Raton, FL: CRC Press; 2010:
18. Hunsberger S,Rubinstein LV,Dancey J,Korn EL.Dose escalation trial designs based on a molecularly targeted endpoint.Stat Med. 2005;24:2171-2181
19. Yin G,Zheng S,Xu J.Two-stage dose finding for cytostatic agents in phase I oncology trials.Stat Med. 2013;32:644-660
20. O’Quigley J,Hughes MD,Fenton T.Dose-finding designs for HIV studies.Biometrics. 2001;57:1018-1029
21. Bretz F,Hsu J,Pinheiro J,Liu Y.Dose finding: a challenge in statistics.Biom J. 2008;50:480-504
22. European Medicines Agency. ICH topic E4: Dose-response information to support drug registration. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E4/Step4/E4_Guideline.pdfAccessed February 19, 2014.
23. Gaydos B,Krams M,Perevozskaya I, et al.Adaptive dose-response studies.Drug Inf J. 2006;40:451-461
24. Bretz F,Pinheiro J,Branson M.Combining multiple comparisons and modeling techniques in dose-response studies.Biometrics. 2005;61:738-748
25. Bornkamp B,Bretz F,Dette H,Pinheiro J.Response-adaptive dose-finding under model uncertainty.Ann Appl Stat. 2011;5 (2B): 1611-1631
26. Ivanova A,Bolognese JA,Perevozskaya I.Adaptive dose finding based on t statistic for dose-response studies.Stat Med. 2008;27:1581-1592
27. Gooley TA,Martin PJ,Fisher LD,Pettinger M.Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation.Control Clin Trials. 1994;15:450-462
28. Durham SD,Flournoy N,Li W.A sequential design for maximizing the probability of a favourable response.Can J Stat. 1998;26:479-495
29. Ivanova A.A new dose-finding design for bivariate outcomes.Biometrics. 2003;59:1001-1007
30. Thall PF.Bayesian models and decision algorithms for complex early phase clinical trials.Stat Sci. 2010;25:227-244
31. Durham SD,Flournoy N,Rosenberger WF.A random walk rule for phase I clinical trials.Biometrics. 1997;53:745-760
32. Kpamegan EE,Flournoy NOptimum Design 2000. Atkinson ABogacka BZhiglyavsky AA, ed. Norwell, MA: Kluwer Academic Publishers; 2001:
33. Kpamegan EE,Flournoy N.Up-and-down designs for selecting the dose with maximum success probability.Seq Anal. 2008;27:78-96
34. Zohar S,O’Quigley J.Optimal designs for estimating the most successful dose.Stat Med. 2006;25:4311-4320
35. Dragalin V,Fedorov V.Adaptive designs for dose-finding based on efficacy-toxicity response.J Stat Plan Inference. 2006;136:1800-1823
36. Hardwick J,Meyer MC,Stout QF.Directed walk designs for dose-response problems with competing failure modes.Biometrics. 2003;59:229-236
37. Kiefer J,Wolfowitz J.Stochastic estimation of the maximum of a regression function.Ann Math Stat. 1952;23:457-461
38. Rosenberger WF.New directions in adaptive designs.Stat Sci. 1996;11:137-149
39. Thall PF,Russell KT.A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.Biometrics. 1998;54:532-540
40. Thall PF,Cook JD.Dose-finding based on efficacy-toxicity trade-offs.Biometrics. 2004;60:684-693
41. Thall PF,Cook JD,Estey EH.Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.J Biopharm Stat. 2006;16:623-638
42. Thall PF,Nguyen HQ,Estey EH.Patient-specific dose finding based on bivariate outcomes and covariates.Biometrics. 2008;64:1126-1136
43. O’Quigley J,Pepe M,Fisher L.Continual reassessment method: a practical design for phase I clinical studies in cancer.Biometrics. 1990;46:33-48
44. Zohar S,O’Quigley J.Identifying the most successful dose (MSD) in dose-finding studies in cancer.Pharm Stat. 2006;5:187-199
45. Braun TM.The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes.Control Clin Trials. 2002;23:240-256
46. Zhang W,Sargent DJ,Mandrekar S.An adaptive dose-finding design incorporating both toxicity and efficacy.Stat Med. 2006;25:2365-2383
47. Seegers V,Chevret S,Resche-Rigon M.Dose-finding design driven by efficacy in onco-hematology phase I/II trials.Stat Med. 2011;30:1574-1583
48. Zhong W,Koopmeiners JS,Carlin BP.A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.Stat Med. 2012;30:3885-3895
49. Whitehead J,Zhou Y,Stevens J,Blakey G.An evaluation of a Bayesian method of dose escalation based on bivariate binary responses.J Biopharm Stat. 2004;14:969-983
50. Whitehead J,Zhou Y,Stevens J,Blakey G,Price J,Leadbetter J.Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit.Stat Med. 2006;25:37-53
51. Loke YC,Tan SB,Cai YY,Machin D.A Bayesian dose finding design for dual endpoint phase I trials.Stat Med. 2006;25:3-22
52. Wang M,Day R.Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.J Biopharm Stat. 2010;20:125-144
53. Houede N,Thall PF,Nguyen H,Paoletti X,Kramar A.Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.Biometrics. 2010;66:532-540
54. Dragalin V,Fedorov V,Wu Y.Two-stage design for dose-finding that accounts for both efficacy and safety.Stat Med. 2008;27:5156-5176
55. Bekele BN,Shen Y.A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.Biometrics. 2005;61:344-354
56. Zhou Y,Whitehead J,Bonvini E,Stevens JW.Bayesian decision procedures for binary and continuous bivariate dose-escalation studies.Pharm Stat. 2006;5:125-133
57. Hirakawa A.An adaptive dose finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.Stat Med. 2012;516 (532): 31
58. Yuan Y,Yin G.Bayesian dose finding by jointly modeling toxicity and efficacy as time-to-event outcomes.Appl Stat. 2009;58:719-736
59. Lei X,Yuan Y,Yin G.Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity.Lifetime Data Anal. 2011;17:156-174
60. Mandrekar SJ,Cui Y,Sargent DJ.An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.Stat Med. 2007;26:2317-2330
61. Huang X,Biswas S,Oki Y,Issa JP,Berry DA.A parallel phase I/II clinical trial design for combination therapies.Biometrics. 2007;63:429-436
62. Dragalin V,Fedorov V,Wu Y.Adaptive designs for selecting drug combinations based on efficacy-toxicity response.J Stat Plan Inference. 2008;138:352-373
63. Li Y,Bekele BN,Ji Y,Cook JD.Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.Stat Med. 2008;27:4895-4913
64. Zhang J,Braun T.A phase I Bayesian adaptive design to simultaneously optimize dose and schedule assignments both between and within patients.J Am Stat Assoc. 2013;108:892-901
65. Ruberg SL.,Dose response studies I.Some design considerations.J Biopharm Stat. 1995;5:1-14
66. Ruberg SL.,Dose response studies II.Analysis and interpretation.J Biopharm Stat. 1995;5:15-42
67. Phillips A.A review of the performance of tests used to establish whether there is a drug effect in dose-response studies.Drug Inf J. 1998;32:683-692
68. Hochberg Y,Tamhane ACMultiple Comparison Procedures. New York, NY: Wiley; 1987:
69. Neuhäuser M,Liu PY,Hothorn LA.Jonckheere’s test, a modification and a maximum test.Biom J. 1998;40:899-909
70. Bretz F.An extension of the Williams trend test to general unbalanced linear models.Comput Stat Data Anal. 2006;50:1735-1748
71. Hothorn LA,Djira GD.A ratio-to-control Williams-type test for trend.Pharm Stat. 2011;10:289-292
72. Hothorn LA,Bretz F.Cochran-Armitage trend test vs. maximum tests.Biom J. 2000;42:553-567
73. Dunnett CW.A multiple comparison procedure for comparing several treatments with a control.J Am Stat Assoc. 1955;50:1096-1121
74. Tamhane AC,Logan BRDose Finding in Drug Development. Ting N, ed. New York, NY: Springer; 2006:chap.
75. Dragalin V,Hsuan F,Padmanabhan SK.Adaptive designs for dose-finding studies based on sigmoid Emax model.J Biopharm Stat. 2007;17:1051-1070
76. Miller F,Guilbaud O,Dette H.Optimal designs for estimating the interesting part of a dose-effect curve.J Biopharm Stat. 2007;17:1097-1115
77. Hu C,Dong Y.Estimating the predictive quality of dose-response after model selection.Stat Med. 2007;26:3114-3139
78. Bornkamp B,Bretz F,Pinheiro J,Dette H.MCPMod: an R package for the design and analysis of dose-finding studies.J Stat Software. 2009;29:1-23
79. Tymofyeyev Y,Rosenberger WF,Hu F.Implementing optimal allocation in sequential binary response experiments.J Am Stat Assoc. 2007;102:224-234
80. Sverdlov O,Rosenberger WF.On recent advances in optimal allocation designs in clinical trials.J Stat Theory Practice. 2013;7:753-773
81. Hu F,Rosenberger WFThe Theory of Response-Adaptive Randomization in Clinical Trials. New York, NY: Wiley; 2006:
82. Hu F,Zhang LX.Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials.Ann Stat. 2004;32:268-301
83. Zhang LX,Hu F,Cheung SH,Chan WS.Immigrated urn models: theoretical properties and applications.Ann Stat. 2011;39:643-671
84. Perevozskaya I,Rosenberger WF,Haines LM.Optimal design for the proportional odds model.Can J Stat. 2003;31:225-235
85. Fan SK,Chaloner K.Optimal designs and limiting optimal designs for a trinomial response.J Stat Plan Inference. 2004;126:347-360
86. Biedermann S,Dette H,Zhu W.Optimal designs for dose-response models with restricted design spaces.J Am Stat Assoc. 2006;101:747-759
87. Biedermann S,Dette H,Zhu W.Compound optimal designs for percentile estimation in dose-response models with restricted design intervals.J Stat Plan Inference. 2006;137:3838-3847
88. Dette H,Bretz F,Pepelyshev A,Pinheiro J.Optimal designs for dose-finding studies.J Am Stat Assoc. 2008;103:1225-1237
89. Dette H,Kiss C,Bevanda M,Bretz F.Optimal designs for the Emax, log-linear and exponential models.Biometrika. 2010;97:513-518
90. Bretz F,Dette H,Pinheiro J.Practical considerations for optimal designs in clinical dose finding studies.Stat Med. 2010;29:731-742
91. Bornkamp B,Bretz F,Dmitrienko A, et al.Innovative approaches for designing and analyzing adaptive dose-ranging trials.J Biopharm Stat. 2007;17:965-995
92. Dragalin V,Bornkamp B,Bretz F, et al.A simulation study to compare new adaptive dose-ranging designs.Stat Biopharm Res. 2010;487 (512): 2
93. Pinheiro J,Bornkamp B,Bretz F.Design and analysis of dose-finding studies combining multiple comparisons and modeling procedures.J Biopharm Stat. 2006;16:639-656
94. Krams M,Lees KR,Hacke W, et al.ASTIN: An adaptive dose-response study of UK-279,276 in acute ischemic stroke.Stroke. 2003;34:2543-2548
95. Padmanabhan SK,Dragalin V.Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint.Biom J. 2010;52:836-852
96. Smith MK,Jones I,Morris MF,Grieve AP,Tan K.Implementation of a Bayesian adaptive design in a proof of concept study.Pharm Stat. 2006;39 (50): 5
97. Weir CJ,Spiegelhalter DJ,Grieve AP.Flexible design and efficient implementation of adaptive dose-finding studies.J Biopharm Stat. 2007;17:1033-1050
98. Berry SM,Spinelli W,Littman GS, et al.A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug.Clin Trials. 2010;121 (135): 7
99. Pinheiro J,Sax F,Antonijevic Z, et al.Adaptive and model-based dose-ranging trials: quantitative evaluation and recommendations: white paper of the PhRMA working group on adaptive dose-ranging studies.Stat Biopharm Res. 2010;435 (468): 2
100. Rosenberger WF,Haines L.Competing designs for phase I clinical trials: a review.Stat Med. 2002;21:2757-2770
101. Antonijevic Z,Gallo P,Chuang-Stein C, et al.Views on emerging issues pertaining to data monitoring committees for adaptive trials.Therapeutic Innovation & Regulatory Science. 2013;47:495-502